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Abstract 
Life without natural products is unimaginable. It has provided 
mankind with oxygen, water, fire, food, clothing, shelter and 
medicine. Its public health impact is considerably high, 
especially of traditional medicines and nature-based modern 
drugs. The traditional medicines, despite its limitations, are 
addressing the health needs of millions of people worldwide. It 
is estimated that about 65-85% of the world population uses 
traditional medicines for their primary health cares. It is also 
estimated that about 39% of all 520 new approved drugs in 
1983-1994 were natural products and out of that 74% were 
discovered as a result of bio-prospecting from plants used in 
traditional medicines. Traditional medicines are increasingly 
getting more popular mainly because: a) it is holistic system 
with less side effects; b) it is evolving as an evidence-based 
medicine; c) its ethno-medical knowledge is applicable to 
modern drug discovery programs. As there are many diseases 
that cannot be cured by the existing drugs and as there are 
increasing cases of drug resistance, there is urgent need for 
drugs that are effective against these pathogens. Probably, 
traditional medicines could provide a solution in fighting them 
both as a health care delivery mechanism and as a means of 
chemotherapeutic pool. Bhutan is fortunate to be gifted with 
rich natural bio-diversity and rich traditional medical 
knowledge. The positive health impacts of the Bhutanese 
                                              
* I appreciate the comments and suggestions provided by 
John.B.Bremner, who is the Emeritus Professor at the University of 
Wollongong, NSW, Australia. I am also grateful to the Head of PRU, 
Director of ITMS and my fellow researchers for their 
encouragements, advises and supports for making this paper a 
success. 
** Research In-charge, PRU, ITMS, MoH. 
 Impacts of Traditional Medicines 
 117
traditional medicines are resoundingly felt by Bhutanese. 
Besides, there is huge potential for bio-prospecting in Bhutan. 
This paper highlights world scenario on the health impacts of 
the: 1) natural product-based traditional medicines, 2) the 
natural product-based drug discoveries, and 3) Bhutanese 
traditional medicine and potential of bio-prospecting in Bhutan. 
Introduction 
With the advancement in science and technology, remarkable 
progress has been made in the field of medicine including 
diagnosis, treatments and pharmaceutics. Recent drug 
discovery techniques based on structure activity 
relationships, computer modeling, combinatorial chemistry, 
high throughput screening and spectroscopy (MS, NMR, and 
IR) have triggered and spearheaded the discoveries of many 
natural and synthetic drugs. In 1999, world sales of 
pharmaceuticals (excluding veterinary medicines) were valued 
at ca. US$ 325 billion.  
 
Despite these developments, of the known 30,000 human 
diseases or disorders, only one-third can some how be treated 
symptomatically with drugs and that too at a great economic 
and social cost. This is because of the fact that the drugs 
available today are still not very effective particularly with 
respect to the fight against drug resistant pathogens and 
newly emerging infections. This includes infectious diseases 
such as AIDS, influenza, tuberculosis and malaria as well as 
other chronic disorders like cancer, autoimmune disorders 
and central nervous system disabilities (e.g. Alzheimer’s 
disease).  They are incurable and often fatal causing great 
suffering and disability.  
 
Hence, these diseases including resistant pathogens are of 
special concern to communities worldwide. There is an urgent 
need to find concrete solutions for combating such epidemics. 
Prevention of famine, drought, poverty, flood, war, political 
upheaval, economic failure, environmental depletion and 
pollution would be good solutions to reduce infections and 
the development of resistance. Strengthening and developing 
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traditional medicines through evidence-based research for 
use against the diseases especially the chronic ones and also 
against drug resistant pathogens is another potential area. 
Another most important strategy to combat both new as well 
as the re-emerging infectious diseases is to develop an 
arsenal of new drugs.   
 
New drugs could be developed synthetically, but experience 
has taught us that the natural products are rich in 
structurally diverse bioactive molecules that quite often 
become potential candidates for new drugs. In fact, in 1996, 
six out of the top 20 pharmaceutical prescription drugs 
dispensed were natural products. Therefore, it is very 
important that mankind value and appreciate the role and 
impacts of natural products, traditional medicines and 
modern drugs discovered from natural products. 
 
This paper presents the role and the impacts of the natural 
products, traditional medicines and the nature-based drug 
discoveries. It also describes the potential, constraints and 
future directions in the area of natural product-based 
traditional medicines and nature-based drug discovery 
programs accentuating Bhutan’s perspectives.  
Traditional medicines and their health impacts  
Mankind has discovered medicinal plants as indispensable 
cures for many ailments. Although some cultures used 
individual natural products as medicines, many traditions 
propounded powerful combinations with different ingredients 
known as poultices, tinctures and mixtures. It is reported 
that the Mesopotamians were the first people to use the herbs 
like oils of cypress, cedar, liquorice and poppy juice for 
treating different ailments in  2600 B.C. Buddhist system of 
medicine known as gSo-ba Rig-pa that is currently practiced 
in Bhutan, Tibet and Mongolia is 2500 years old and its 
pharmacopoea records the use of  as many as 2200 
traditional prescription drugs.   
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In 1500 BC, Egyptian’s developed the Ebers Papyrus that 
documented some of the 700 drugs including formulas such 
as gargles, snuffs, poultices, infusions, pills and ointments. 
The Chinese materia medica Wu-Shi Er-Bing Fang which 
contains 52 prescriptions date back to 1100 BC and the 
Indian Ayurvedic Medicine that dates to 1000 BC (Susruta 
and Charaka) documents the medicinal use of plants like 
datura, aconitum, canabis and sarcostemma.    
 
From these ancient cultures, some of the knowledge reached 
Mediterranean countries through traders and migrations, and 
it was in Hippocrates’s time in 460-377 BC that 
pharmacognosy reached its summit in Greece. In 300 to 322 
BC, Theophrastus, who was a philosopher and naturalist, 
was the first to deal with the history of plants, which later on 
helped in the classification of plants, including herbs. In 78 
AD, Pedanius Dioscorides, a Greek physician produced De 
materia medica, which described more than 500 medicinal 
plants and their uses in detail.  
 
Galen (ca 129-199 AD) founded “Galenics” and taught 
pharmacy and medicine in Rome. Avicenna (980-1037 AD), a 
Persian pharmacist, physician, philosopher and a poet, 
described 1400 drugs and medicinal plants which greatly 
contributed to the formation of a codified Graeco-Roman 
Medicine in the 5th century. Paracelsus (1493-1541) 
administered dosage formulations separating “Arkanum” from 
non-active ingredients of drugs. Western medicine and 
pharmacy originated from this medical system.  
 
In the USA, homeopathy that includes hydrotherapy, 
nutritional therapy, herbal therapy, manual manipulation 
and midwifery, which were founded by German physician 
Hahnemann (1755-18-43), became popular in 1830s. The 
National Centre for Complementary and Alternative Medicine 
(NCCAM) was established at the National Institute of Health, 
USA in the 1990s to independently develop and support 
research on Complementary and Alternative Medicine. The 
NCCAM categorised seven forms of therapies practiced 
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worldwide such as mind-body interventions, bio-
electromagnetic therapies, alternative systems of medical 
practice, manual healing methods, pharmacological and 
biological treatments, herbal medicine and diet and nutrition. 
 
The discovery of antibiotics and vaccines in the 20th century 
dramatically changed medical practice worldwide, and as a 
result a separate field of ethno-medicine emerged as an 
academic specialization focusing on traditional healing 
systems. Today, traditional medicines effectively addresses 
the health needs of millions of people including developed 
nations by completely different strategies and well defined 
approaches, and generally with minimal side effects. Current 
WHO estimates show that 75% of the French population, 30% 
of the Vietnamese population, and 40% of Indonesia’s 
population uses traditional medicines; 77% of pain clinics 
provide acupuncture in Germany and 72% of registered 
western style doctors uses kampo medicine in Japan. In 
Bhutan, traditional medicine is an integral part of the health 
care delivery system. Almost 100% of Hospitals and some 
Basic Health Units provide traditional medical services.  
 
Overall, traditional medicines provide primary health care 
needs to almost 65-85% of the world’s population, including 
developed nations. In terms of economic value, traditional 
therapies contribute to US $ 60 billion a year, and the USA 
alone spends US $ 2.7 billion per year followed by China with 
US $ 1.8 billion and Australia with Aus $ 1 billion a year. In 
fact, the traditional medicine is gaining popularity worldwide 
and this is attributable to four of their main salient features: 
the use of natural products as ingredients, the concept of 
holism with minimal side effects as opposed to allopathic 
drugs, the emerging clinical efficacy and the content of 
reservoir of ethno-medical information.  
 
As required by the WHO regulations, many traditional 
medicines are strictly monitored for their quality, safety and 
efficacy. Many traditional medical systems including 
Japanese Traditional Sino-medicine and Tibetan medicine 
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(gso-ba-rig-pa) have emerged as evidence-based medicines. 
For example, the investigation on the principal of drug action 
of the Japanese Traditional Sino-medicine resulted in 
obtaining many novel compounds and unknown new 
mechanisms of drug action. The clinical trials of Tibetan 
medicine, the PADMA Products also proved successful on 
treatment of Irritable Bowel Syndrome and fibrinolysis with 
stable intermittent claudication. It furnished new anti-
oxidative mechanisms at the molecular level.  
 
Thus, all these indicates that traditional medicines caters to 
millions of peoples worldwide in their primary health care 
needs.  
Bio-prospecting and their health impacts 
Other than providing primary health care, the natural 
products also play significant role in the discovery of the 
natural product-based drugs. The natural products like 
plants, animals, microorganisms, marine organisms and the 
extremophiles have been an important sources of the 
potential drug leads and this will continue for years to come. 
Many bioactive molecules have been isolated from these 
sources applying three main types of search strategies: bio-
rational, chemo-rational and random approaches. For 
example, Conocurvone-an anti-HIV agent was discovered as a 
result of random approach of screening. Drugs such as 
artemisinin, morphine, quinine, and ephedrine were 
discovered using bio-rational approach. Out of these three 
search strategies, bio-rational approach is the most effective 
one. Bio-rational approach is mostly guided by the ethno-
medical information generated from the traditional medicines. 
More than 13,000 species of plants are being used in the 
traditional medicines and herbal cosmetics and about 8000 of 
these medicinal plants species are known in South Asia 
alone. These natural products (medicinal plants) contain 
reservoir of etho-medical and ethno-botanical information, 
which is an important guide to discovery of many new drug 
lead molecules.  
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Recently at the National Cancer Institute (NCI, USA), 
although random high throughput screening method 
furnished a large number of testing extracts, it was found by 
in vitro bioassays that medicinal plants from traditional 
medicines gave greater rates of bioactivity. At the University 
of Illinois, Chicago, out of 800 medicinal plant extracts 
collected from Vietnam and Laos, at least 25 biologically 
active compounds were isolated; of these 13 were new anti-
HIV agents and 3 were anti-malarial agents. In the USA, out 
of 119 plant drugs available from 1959 to 1980, 74% of these 
were discovered as a result of chemical studies directed at 
isolating the active substances from the plants used in 
traditional medicines. In fact, Cragg et al. estimated that 39% 
of all 520 new approved drugs in 1983-1994 were natural 
products, and 60-80% of antibacterial and anti-cancer drugs 
were derived from natural products. Analysing the USA based 
community prescriptions in 1973, it was found out that 
25.2% of the prescription drugs were plant derivatives, 13.3% 
were microbial derivatives and 2.7% were animal derivatives.  
 
The search for new drugs continues, but mostly using the 
ethno-directed bio-rational approach. In 1999, the 
NAPRALERT database recorded more than 88,000 natural 
product isolates and many of them formed the skeletal 
framework of many renowned drugs available in the market 
today. For example, mevastatin (compactin) and lovastatin 
which were isolated from Penicillin spp became the cholesterol 
lowering drugs. Ivermectins isolated from the  streptomycetes 
spp became an anthelmintic and antiparasitic drug. 
Reserpine was isolated from the plant rauwolfia serpentine 
and was turned into antihypertensive drug. Ephedrine 
isolated in 1923 from ephedra sinca formed the basis for the 
synthesis of salbutamol and salmetrol which are the anti-
asthma drugs (beta agonist). Atropine comes from belladonna 
and even aspirin was derived from salicin present in willow 
bark. Teprotide was isolated from the venom of the pit viper, 
bothrops jaracaca and this formed the skeletal framework of 
the captropril and enalopril, which are used in treating 
cardiovascular diseases.  
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In the class of anti-cancer drugs, the vincristine and 
vinblastine isolated from catharanthus roseus are clinically 
used as the anti-cancer drugs today. Another anti-cancer 
agent, paclitaxel (taxol) was discovered from pacific yew, 
taxus brevifolia. Semi-synthetic drugs topotecan and 
irrinotecan were derived from camptothecian that was 
isolated from Chinese ornamental tree, camtotheca acuminate. 
An anti-tumor agent, podophylotoxin isolated from the roots 
podophylum peltatum is effective in treating skin cancer and 
the warts. Its semi-synthetic derivatives, etoposide and 
teniposide, is used against the lung and testicular cancers, 
lymphomas and leukemia and against the acute lymphatic 
leukemia, neuroblastoma in children, non-hodgkin’s 
lymphomas and tumors in adults respectively. In the mid 
1980s, bryostatin-1 was isolated from bugula neritina, a 
marine bryozoans, and was found effective against ovarian 
carcinoma and non-Hodgkin’s’ lymphoma. Aplidine, isolated 
from trididemum solidum, a marine tunicate is in phase II 
clinical trials in Europe. Ecteinascidin 743, a metabolite from 
ectelinascidia turbinate tested for in vivo activity against the 
murine B16 malanoma and human MX-1 breast carcinoma 
models, is currently in Phase II clinical trials in Europe and 
US. Squalamine isolated from squalus acanthias is in phase-I 
clinical trial. 
 
In the line of antimicrobial and anti-plasmodial drugs, 
microorganisms have been the popular source of antibiotics, 
ever since the discovery of penicillin from the filamentous 
fungus penicillium notatum by Alexander Fleming in 1928. 
Cyclosporins and rapamycin (an immunosuppressive agent), 
streptomycin, chloramphenicol, tetracyclines and 
cephalosporin (antibiotics) were isolated from the 
streptomyces and penicillium species. Provir, an oral product 
for the treatment of respiratory viral infections, and virend, a 
topical antiviral product for the treatment of herpes (both in 
clinical trials), were very recently developed from plant 
alkaloids. The sulphonamides were the first group of effective 
anti-bacterials to be developed following a chance discovery of 
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antibacterial activity in synthetic Azo-dye-prontosil in 1932 
by Dogmak, and since then many antibacterial drugs were 
developed in between the late 1940s to 1980s. By then most 
of the infectious diseases were almost eradicated in the 
developed world, and as a result, almost half the major 
pharmaceutical companies in Japan and the USA stopped 
their antibacterial drug development programs. Even today, 
antibacterial agents make up only 12-15% of the total 
pharmaceutical business, and thus, there are very few drugs 
that are effective against the infectious bacterial pathogens 
especially the resistant bacteria.  
 
As there are many diseases that cannot be treated by the 
existing drugs and also as the drug resistance by many 
pathogens are increasing, it is evident that there is need for 
the development of new arsenal of drugs to combat them be it 
synthetically or based on the natural products. The World 
Health Organization has estimated that about 50,000 people 
die worldwide every year from infectious diseases alone. The 
lead cause of death is HIV-AIDS, followed by tuberculosis and 
malaria. In 1996, the approximate figure showed that the HIV 
virus had infected at least 21,000,000 people worldwide and 
in 2001, UNAIDS estimated that over 14,000 new infections 
occur daily, nearly half of them in women and strikingly 
affecting Africa. While malaria continues to claim 1-3 million 
lives each year, ca. 2 billion people including at least 15 
million Americans are affected by tuberculosis.  
 
These infectious diseases (microbial) will continue to be the 
leading cause of premature death in human beings of both 
developed and developing nations as their resistance to many 
conventional drugs is increasing. For example, plasmodium 
falciparum have already developed resistance to the existing 
traditional anti-malarial drugs like quinine, chloroquene 
mefloquene and even to the second line drug pyrimethamine-
sulphadoxine (fansidar) and halofantrine. The resistance to 
the combined drug therapy has been reported in Africa, 
Thailand, Burma, Laos, Vietnam, Cambodia and China and 
there is hardly any anti-malarial drugs in line to fight the 
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resistance. The latest anti-malarial drugs artimisinin and its 
derivatives, artemether and artether, isolated from artemesia 
annua is the only effective anti-malarial drugs available in the 
market. This is the only hope of saving millions of lives 
especially in Sub-Saharan Africa where children are affected 
worst.  
 
Similarly, many anti-bacterial, anti-fungal and antiviral drugs 
are becoming obsolete as the microbes have evolved 
numerous defenses against antimicrobial agents and drug-
resistant pathogens are on the rise. The first resistance case 
was reported as soon as the introduction of chemotherapy in 
staphylococcus aureus in 1941. Mycobacterium tuberculosis 
that causes tuberculosis emerged resistant to streptomycin in 
1940s and by 1950s and 1960s, it also developed resistance 
to later drugs isoniazid and rifamycins. Streptococci that 
causes nosocomial infections showed innate resistance to 
drugs, including cephalosporins, clindamycin and 
aminoglycoside. The Staphylococcus aureus have currently 
developed into multi-drug resistant strain and threaten to put 
an end to successful chemotherapy. Vancomycin resistance 
among enterococci became noticeable in 1987 and has 
resulted into a true ‘super bug’. The summary of bacterial 
resistance to chemotherapy is shown in table 1. 
 
Table 1.   Bacteria that have acquired resistance to some drug 
therapy. 
Resistant  
type 
Bacteria Disorders Date 
(approx.) 
Penicillin  
resistant 
Pneumococci 
 
Legionella 
 
Borrelia 
burgdorferi 
Salmonella 
 
Staphylococci 
 
E.coli O157:H7 
Pneumonia & 
meningitis 
Legionnaire’s  
disease 
Lyme disease 
 
Gastrointestinal 
disorders 
Toxic shock  
syndrome 
Gastrointestinal 
Mid 1970s- 
present 
Mid 1970s- 
present 
1980s-
present 
1980s-
present 
1980s 
 
Mid 1980s- 
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disorders present 
Multi-drug  
resistant 
M.tuberculosis Tuberculosis Late 1980s- 
present 
Vancomycin 
resistant 
Enterococci 
V.cholerae 
Wound, blood,  
enteric infections 
Cholera 
Late 1980s- 
present 
Multi-drug  
resistant  
“super bugs”  2002-present 
Source: Dax, S.L. Antibacterial Chemotherapeutic Agents. First ed. 
London, UK: Blakie Academic & Professional, Chapman & Hall. 1997. 
  
Thus, there is immediate need to find new anti-microbial 
drugs active against the resistant  and re-emerging diseases. 
It would be only wiser and better to turn to nature for finding 
new and effective drugs. It is estimated that ca. 250,000 to 
500,000 species of plants grow on earth but only 10-15% of 
such species are reported to have been studied 
phytochemically for medicinal applications. There are 30 
million species of insects and very few have been studied for 
bioactive molecules. Marine world represent 70% of earth’s 
surface but only 5% of the marine organisms are explored. 
Only an estimated 1% of bacterial and 5% of fungal species 
have been examined to date. Extremophiles such as 
alkalophiles, halophiles, barophiles, thermophiles and 
psychrophiles have been neglected so far. These 
extremophiles would definitely offer a potentially diverse 
source of novel bioactive molecules.  
 
All the above reviewed figures suggest only one thing: that is, 
the natural sources are least explored for medicinal 
applications despite the huge availability of the natural 
resources and immense potential for discovery of new drugs. 
When there is need for the new drugs, it is only befitting to 
systematically explore the rich natural resources and may be 
even the drugs for HIV-AIDS can be discovered. This would 
save millions of lives worldwide and definitely this means 
positive impacts to the health of the people worldwide. 
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Bhutanese traditional medicine: Its health impact and the 
potential of bio-prospecting. 
Bhutan is rich in traditional-cultural diversity and natural 
resources. Probably, the rich natural resources hosted by the 
un-scalable topography of the country facilitated the growth 
of luxurious traditions and cultures. Such phenomenal gifts 
are rare to find in many countries. One of the tangible 
traditional assets of Bhutan is the traditional medical 
practices.  Bhutan  host two forms of traditional medicines: 
local healing practices and the formalized traditional medical 
system which is locally known as gSo-ba-rig-pa (Bhutanese 
Traditional Medicine). While local healing practices are an 
oral medical traditions that lacks proper documentation, gSo-
ba-rig-pa medical system is highly sophisticated and fully 
documented. It is based on Buddhist philosophy and adopted 
principles of Chinese Traditional Medicine, Indian Ayurvedic 
Medicine and Persian Medicine.  
 
Some sources noted that gSo-ba-rig-pa in Bhutan took shape 
with the advent of Mahayana Buddhism from Tibet in the 8th 
century, but there are other sources stating that gSo-ba-rig-
pa developed subsequently in Tibet and Bhutan during the 
coming in of great Buddhist saint called Guru Padma 
Sambhava from India in the eight century. However, for sure 
it is clear that gSo-ba-rig-pa in Bhutan originated in the 8th 
century under the tutelage of Guru Rimpoche.  This is 
substantiated by the fact that Khandro Yeshi Tshogyal, a 
consort and a disciple of Guru Rimpoche meditated on rdu-
rtsi sman-gi-bchued-lan brgya-tsa brgyad at Mon-kha Nye-
ring, Singye Dzong. In 1616, during the reign of Shabdrung 
Ngawang Namgyal, Minister of Religion, Tenzing Drukgyal, 
who was an esteemed physician started the propagation of 
gSo-ba-rig-pa in Bhutan. After the year 1885, the Penlops 
and Dzongpons and Desis patronized the profession by 
privately employing an esteemed physicians trained in gSo-
ba-rig-pa. Drungtsho Pemba was the personal physician to 
the first King. Drungtsho Penjor and Mahaguru served at the 
court of the second King. In 1967, the third King, Jigme Dorji 
Wangchuck ordered the establishment of a separate 
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traditional medicine dispensary at Dechencholing, Thimphu. 
In 1971, formal training for Drungtshos (traditional doctors) 
and sMenpas (traditional compounders) was initiated in 
Bhutan, providing a solid professional base for gSo-ba-rig-pa. 
Today, gSo-ba-rig-pa has been integrated with the modern 
health care system and ultimately broadened the health care 
choices to the patients. Only few countries support the 
practices of traditional medical system along side biomedicine 
and even fewer countries (e.g. Bhutan, China, Mongolia and 
Vietnam) officially recognize and support one integrated 
medical system under same Ministry and Health Care 
Delivery System. This experience of integrating two 
conceptually very different health care systems within one 
ministry contain important managerial lessons to be learnt by 
others.  
 
Currently about 29 traditional medicine units attached to 
modern district hospitals and the Basic Health Units (BHUs) 
functions efficiently under the guardianship of the Institute of 
Traditional Medicine Services (ITMS). The ITMS manufactures 
about 98 different essential traditional medicines using 300 
different medicinal ingredients. The National Traditional 
Medicine Hospital in Thimphu alone treats more than 30,000 
patients annually and the district Traditional Medicine Units 
treats about 20-30% of the total daily OPD patients of the 
district hospital. gSo-ba-rig-pa is getting more popular 
amongst the Bhutanese populace. It is also attracting 
international interests after it is being recognized by the 
World Health Organization as one of the important traditional 
medical system responsible for delivering primary health 
cares. Such popularities would mean pressure on the supply 
of traditional medicines thereby emasculating its 
sustainability. To achieve sustainability in raw materials and 
traditional medicines, ITMS and the Medicinal and Aromatic 
Plant Section (MAPS) under Ministry of Agriculture have 
jointly initiated the inventory development, domestication and 
cultivation trials of the rare and endangered medicinal plants 
species.  
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Beside providing health cares, gSo-ba-rig-pa also forms a 
unique opportunity for bio-prospecting in Bhutan since it is 
rich in ethno-medical information. The Bhutanese flora and 
fauna are characterized by an outstanding bio-diversity and a 
large number of endemic species, many of which forms part of 
the gSo-ba-rig-pa pharmacopoeia. Therefore, Bhutan’s rich 
bio-diversity may be hosting cures for many diseases 
including AIDS, cancer and other infectious diseases.  
 
Recently, a research carried out at the University of 
Wollongong on two Bhutanese medicinal plants aconitum 
orochryseum and corydalis gerdae revealed three new and 
four known novel compounds with significant antimalarial 
activities against resistant strains of plasmodium falciparum. 
Further study on this finding would also result in obtaining 
unknown new mechanisms of drug action.  
 
Many medicinal plants such as aquilaria agallocha, rauwolfia 
serpentina, paris polyphylla, sapindus mukorossi, phyllanthus 
emblica, terminalia bellirica, terminalia chebula,  ephedra 
gerardina, taxus bacccata, rheum nobile, rheum accuminata, 
picrorhiza kurroa, podophyllum hexandrum, nardostachys 
jatamansi, aconitum species, artemisia species, panax pseudo-
ginseng sub-species himalaicus and cordyceps sinensis are in 
high demand for pharmaceuticals and cosmetics. 
Commercializing and bio-prospecting these medicinal plants 
would not only accelerate the Bhutan’s economic growth, but 
also contribute to the global stock of pharmaceuticals. Thus, 
gSo-ba-rig-pa (Bhutanese traditional medicine) has lots of 
potentials in terms of the provision of the primary health care 
as well as in the discovery of new drugs if strategically 
managed and developed considering the innate intellectual 
property rights. 
Conclusion and future directions 
Natural products have been the basis for the formation of 
traditional medicines and for the discoveries of many modern 
drugs. Without the natural products, life will cease to 
function, and almost every cultures and traditions including 
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the traditional medicines and drug discoveries can be 
handicapped. This is because the flora and fauna of our 
planet provide at least 50% of all pharmaceuticals and almost 
85% of the world’s population depend on traditional 
medicines for their primary health care needs, which will 
continue forever.  
 
In many countries, traditional medicines are deeply rooted in 
their cultures. It has become an indispensable treatment 
regimens and a subject of interests for the pharmaceutical 
companies for the following reasons: a) it is holistic in nature 
and has no side effects as opposed to modern allopathic 
drugs; b) the traditional medicines are cheap and easily 
available in the markets (raw materials), especially in 
developing countries as compared to modern drugs which are 
very expensive; c) most of the traditional medical systems are 
supported by long clinical use with properly recorded 
pharmacopoeias and are being supported by the scientific 
validation processes; and d) traditional medicines are the 
reservoirs of ethno-medical and ethno-botanical information 
which are the keys for opening many new modern drug leads.  
 
As the diseases are increasingly developing resistance to the 
existing drugs and as there are newly emerging disorders, it is 
only natural that the natural products, traditional medicines 
and drug discovery programs will even become more 
indispensable. In an effort to fight the diseases, disorders and 
sufferings; there is urgent need for new and effective arsenal 
of drugs (applies to allopathic as well as traditional 
medicines). The world still has 80-85% of the natural 
products unexplored for medicinal applications. The effective 
medicines can be discovered only through trans-disciplinary 
co-operations and collaborations among the scientists, 
medical doctors and traditional physicians. It will not help 
anybody by professional turf building, working on the 
professional economic gain and the politicizations of the 
medical practices and pharmaceutical works. Health care is 
more likely to be integrative, holistic, safe and effective when 
medical practitioners (conventional and traditional medicines) 
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and scientists consider the welfare of the client or patients 
above their own interests.  
 
There is also immediate need for country to country co-
operations and collaborations. Some developing countries are 
extremely rich in biodiversity and traditional medical 
knowledge but lacks the technologies and financial resources 
to meaningfully explore and add value to them. On the 
contrary, the developed countries are rich in technologies and 
financial resources but lacks in the natural resources and the 
traditional medical knowledge. It would be better to come 
together, bridge these gaps and differences and come up with 
effective cures for the un-forgiving diseases.  
 
Bhutan is fortunate to be gifted with rich biodiversity and 
traditional medical knowledge that could pioneer successful 
bio-prospecting. However, like any other developing countries, 
Bhutan lacks technical expertise and financial resources to 
explore them meaningfully. The only option Bhutan have is to 
collaborate with the developed nations and interested 
pharmaceutical companies alike and jointly explore them 
strategically and wisely. In doing so, the model of 
collaboration should be such that it builds the science 
infrastructure within, preserve and protect the local 
traditional medical knowledge reducing the brain drain, and 
equally share the outcome of the joint projects. While bio-
prospecting should gear up, strengthening the Bhutanese 
traditional medicine should be a simultaneous effort since it 
has multi-pronged benefits. First, it has significant 
contribution to the health of the Bhutanese; second it is 
manufactured in Bhutan using the country’s luxurious 
medicinal plants and other raw materials benefiting many 
businesses and farmers; third, it provide employment 
opportunities; and fourth, it uses more than 300 medicinal 
materials that could be useful for bio-prospecting. In fact, it is 
the nerve centre with many development networks that 
promotes ethical and sustainable utilization of bio-resources 
to benefit farmers, business people, human health and the 
environment in Bhutan. This traditional medical system 
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embraces all the four pillars of Gross National Happiness. 
Also, it will be a yardstick for the discovery of new drug leads 
that could save millions of lives. It is therefore important that 
there is continuing support for protecting, promoting, and 
propagating this traditional medicine and also in preserving 
our rich biodiversity. Perhaps, our biodiversity may be 
hosting cures for HIV-AIDS, Cancer, Hipatitis B and many 
other chronic diseases. 
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